In vivo infection models in the pre‐clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current opinion in pharmacology (Print)

• Publication date

  2017-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.coph.2017.09.004PMID 28964956
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus

  2017cited by this paper
• In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

  2017cited by this paper
• In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model

  2016cited by this paper
• Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models

  2016cited by this paper
• Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.

  2016cited by this paper
• Efficacy of Humanized High-Dose Meropenem, Cefepime, and Levofloxacin against Enterobacteriaceae Isolates Producing Verona Integron-Encoded Metallo-β-Lactamase (VIM) in a Murine Thigh Infection Model

  2015cited by this paper
• Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target

  2015cited by this paper
• Pharmacokinetic-Pharmacodynamic Analysis for Efficacy of Ceftaroline Fosamil in Patients with Acute Bacterial Skin and Skin Structure Infections

  2014cited by this paper
• Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.

  2014cited by this paper
• Impact of MIC Range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the Ceftolozane In Vivo Pharmacokinetic/Pharmacodynamic Target

  2014cited by this paper
• Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at Inocula of 105 and 107 CFU Injected into Opposite Thighs of Neutropenic Mice

  2013cited by this paper
• Comparative efficacy of human simulated exposures of tedizold and linezolid against Staphylococcus aureus in the murine thigh infection model

  2012cited by this paper
• Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid

  2011cited by this paper
• Meropenem Penetration into Epithelial Lining Fluid in Mice and Humans and Delineation of Exposure Targets

  2011cited by this paper
• Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia

  2011cited by this paper
• Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid

  2011cited by this paper
• Protein Binding: Do We Ever Learn?

  2011cited by this paper
• Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!

  2010cited by this paper
• Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole

  2009cited by this paper
• Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.

  2008cited by this paper
• In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection Models

  2008cited by this paper
• Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design.

  2008cited by this paper
• Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

  2007cited by this paper
• Pharmacodynamics of a New Streptogramin, XRP 2868, in Murine Thigh and Lung Infection Models

  2006cited by this paper
• Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.

  2005cited by this paper
• Determination of the In Vivo Pharmacodynamic Profile of Cefepime against Extended-Spectrum-Beta-Lactamase-Producing Escherichia coli at Various Inocula

  2004cited by this paper
• Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models

  2002cited by this paper
• Animal model pharmacokinetics and pharmacodynamics: a critical review.

  2002cited by this paper
• Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

  1998cited by this paper

• Pharmacodynamic evaluation of BRII-693, a next-generation synthetic macrocyclic peptide antibiotic, in the neutropenic mouse thigh and lung infection models against gram-negative pathogens

  2026cites this paper
• Exploiting Pharmacokinetic/Pharmacodynamic Methods for Optimizing and Accelerating Drug Development of Innovative Anti‐Infectives

  2026cites this paper
• Natural Products as Potentiators of β-Lactam Antibiotics: A Review of Mechanisms, Advances, and Future Directions.

  2026cites this paper
• The COMBINE pneumonia model: a multicenter study to standardize a mouse pneumonia model with Pseudomonas aeruginosa and Klebsiella pneumoniae for antibiotic development

  2026influential citation
• Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections

  2025cites this paper
• Navigating the complexities of drug development for metallo-β-lactamase inhibitors

  2025cites this paper
• Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa

  2024cites this paper
• Animal Models in Regulatory Breakpoint Determination: Review of New Drug Applications of Approved Antibiotics from 2014–2022

  2024cites this paper
• Preclinical and Clinical Studies in the Drug Development Process of EMA-approved non-HIV antiviral agents: A Narrative review.

  2024cites this paper
• Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study.

  2024cites this paper
• Isolation, Identification, and Antimicrobial Evaluation of Secondary Metabolite from Serratia marcescens via an In Vivo Epicutaneous Infection Model

  2024cites this paper
• Aerosolized delivery of ESKAPE pathogens for murine pneumonia models

  2024cites this paper
• Translational PK/PD for the Development of Novel Antibiotics—A Drug Developer’s Perspective

  2024cites this paper
• In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model

  2023cites this paper
• Discovery and druggability evaluation of pyrrolamide-type GyrB/ParE inhibitor against drug-resistant bacterial infection

  2023influential citation
• Bacterial pathogens: Potential source for antimicrobial peptides.

  2023cites this paper
• Neutropenic Rat Thigh Infection Model for Evaluation of the Pharmacokinetics/Pharmacodynamics of Anti-Infectives

  2023cites this paper
• Preclinical performance testing of medical devices with antimicrobial effects

  2023cites this paper
• All Roads Lead to Rome: Enhancing the Probability of Target Attainment with Different Pharmacokinetic/Pharmacodynamic Modelling Approaches

  2023cites this paper
• Pharmacokinetic/Pharmacodynamic Index Linked to In Vivo Efficacy of the Ampicillin-Ceftriaxone Combination against Enterococcus faecalis

  2023cites this paper
• Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48.

  2023cites this paper
• Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections

  2022cites this paper
• Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48.

  2022cites this paper
• Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents

  2022cites this paper
• Influence of tramadol on bacterial burden in the standard neutropenic thigh infection model

  2022cites this paper
• Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus

  2022cites this paper
• Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant Staphylococcus aureus

  2021cites this paper
• Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update

  2021cites this paper
• Activity of β-Lactam Antibiotics against Metallo-β-Lactamase-Producing Enterobacterales in Animal Infection Models: a Current State of Affairs

  2021cites this paper
• Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens

  2020cites this paper
• Antimicrobial pharmacokinetics and preclinical in vitro models to support optimized treatment approaches for uncomplicated lower urinary tract infections

  2020cites this paper
• Combatting The Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision.

  2020cites this paper
• Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy

  2020cites this paper
• Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review

  2020cites this paper
• Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model

  2020cites this paper
• Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice.

  2020cites this paper
• Metallo-β-lactamase resistance in Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility testing methods.

  2020cites this paper
• Animal models for research in human infectious diseases. CMI editorial policy.

  2019cites this paper
• Kinetic Driver of Antibacterial Drugs against Plasmodium falciparum and Implications for Clinical Dosing

  2019cites this paper
• Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans

  2019cites this paper
• The antimicrobial potential of Streptomyces from insect microbiomes

  2019cites this paper
• Extended vs Bolus Infusion of Broad-Spectrum &bgr;-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial

  2018cites this paper
• In Vivo Pharmacodynamic Characterization of a Novel Antibiotic Odilorhabdins , 1 NOSO-502 against Escherichia coli and Klebsiella pneumoniae in a Murine 2 Thigh Infection Model 3 4

  2018cites this paper
• The Role of Pharmacometrics in the Development of Antimicrobial Agents

  2018cites this paper
• Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae

  2018cites this paper
• In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model

  2018cites this paper
• In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Danofloxacin in Rabbits Infected With Salmonella typhimurium After Oral Administration

  2018cites this paper
• Clinical pharmacokinetic–pharmacodynamic analyses: a critical element for developing antibacterial agents

  2017cites this paper
• Editorial overview: Use of PK-PD for antibacterial drug development: decreasing risk and paths forward for resistant pathogens.

  2017cites this paper
• Modeling of viral-bacterial infections against antibiotic-induced intestinal dysbiosis

  year unknowncites this paper